Literature DB >> 28093367

Effect of construction of TiO2 nanotubes on platelet behaviors: Structure-property relationships.

Qiaoling Huang1, Yun Yang2, Dajiang Zheng3, Ran Song3, Yanmei Zhang2, Pinliang Jiang3, Erwin A Vogler4, Changjian Lin5.   

Abstract

Blood compatibility of TiO2 nanotubes (TNTs) has been assessed in rabbit platelet-rich plasma (PRP), which combines activation of both blood plasma coagulation and platelets. We find that (i) amorphous TiO2 nanotubes (TNTs) with relatively larger outer diameters led to reduced platelet adhesion/activation, (ii) TNTs with relatively smaller outer diameters in a predominately rutile phase also inhibited platelet adhesion and activation, and (iii) a pervasive fibrin network formed on larger outer diameter TNTs in a predominately anatase phase. Thus, this study suggests that combined effect of crystalline phase and surface chemistry controls blood-contact behavior of TNTs. A more comprehensive mechanism is proposed for understanding hemocompatibility of TiO2 which might prove helpful as a guide to prospective design of TiO2-based biomaterials. STATEMENT OF SIGNIFICANCE: To realize optimal design and construction of biomaterials with desired properties for blood contact materials, a comprehensive understanding of structure-property relationships is required. In the existing literature, TiO2 nanotube has been reported to be a good candidate for biomedical applications. However, it is noticeable that the blood compatibility of TiO2 nanotubes (TNTs) remains obscure or even inconsistent in the previously published works. The inconsistency could derive from different research protocols, material properties or blood sources. Thus, a thorough investigation of the effect of surface properties on blood compatibility is crucial to the development of titanium based materials. In this paper, we explored the effect of surface properties on the response of platelet-rich plasma, especially surface morphology, chemistry, wettability and crystalline phase. The results indicated that crystalline phase was a dominant factor in platelet behaviors. Reduced adhesion and activation of platelets were observed on amorphous and rutile dominated TNTs, whereas anatase dominated TNTs activated the formation of fibrin network. We further proposed a hypothetical mechanism for better understanding of how surface properties affect the response of platelet-rich plasma. Therefore, this study expands the fundamental understanding of the structure-property relationships of titanium based materials.
Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crystalline phase; Diameter; Platelet adhesion; TiO(2) nanotubes; Wettability

Mesh:

Substances:

Year:  2017        PMID: 28093367     DOI: 10.1016/j.actbio.2017.01.044

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  4 in total

1.  Effects of hydrogenated TiO2 nanotube arrays on protein adsorption and compatibility with osteoblast-like cells.

Authors:  Ran Lu; Caiyun Wang; Xin Wang; Yuji Wang; Na Wang; Joshua Chou; Tao Li; Zhenting Zhang; Yunhan Ling; Su Chen
Journal:  Int J Nanomedicine       Date:  2018-04-04

2.  Effects of Surface Nanotopography and Calcium Chemistry of Titanium Bone Implants on Early Blood Platelet and Macrophage Cell Function.

Authors:  Jin-Woo Park; Sang-Hyeob Han; Takao Hanawa
Journal:  Biomed Res Int       Date:  2018-07-04       Impact factor: 3.411

Review 3.  Nanostructured Titanium Implant Surface Facilitating Osseointegration from Protein Adsorption to Osteogenesis: The Example of TiO2 NTAs.

Authors:  Bingfeng Wu; Yufei Tang; Kai Wang; Xuemei Zhou; Lin Xiang
Journal:  Int J Nanomedicine       Date:  2022-04-29

4.  Blood Coagulation on Titanium Dioxide Films with Various Crystal Structures on Titanium Implant Surfaces.

Authors:  Her-Hsiung Huang; Zhi-Hwa Chen; Diem Thuy Nguyen; Chuan-Ming Tseng; Chiang-Sang Chen; Jean-Heng Chang
Journal:  Cells       Date:  2022-08-23       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.